Menopause Relief AM & PM
Natural health product licensed in Canada
- Other names
- Relief AM and PM
- Licence holder
- CICTAN Health Group Corp.
- NPN or DIN-HM
- 80048891
- Status
- Active licence
- Licence date
- 4 March 2014
- Revision date
- Not provided
- Form
- Capsule, dur
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Glycine max. (L.) Merr.: La portion journalière recommandée ne doit pas conduire à une ingestion d'isoflavones supérieure à 1 mg/kg de poids corporel (exprimés comme aglycone du composant principal). L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Actaea racemosa L.: Seuls les extraits aqueux et hydro-alcooliques de titre faible (30 %) sont admis. La portion journalière recommandée ne doit pas conduire à une ingestion de glycosides de triterpène (calculés comme 27-déoxyactéine) supérieure à 3 mg.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Ginkgo biloba L.: L'étiquetage des compléments alimentaires qui contiennent la feuille de la plante Ginkgo biloba L. doit comporter un avertissement avec la teneur suivante: "Consultez votre médecin en cas de prise simultanée d'anticoagulants."
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Glycine max Source : Glycine max - Graine Potency : 7.5 mg ÉAI Genistein | Not specified | Not calculated |
| Actaea racemosa Source : Racine et rhizome Extraction ratio : 6:1 Dry plant equivalent : 120 mg Potency : 2.5 % Triterpene glycosides | 20 mg | Not calculated |
| Glycine max Source : Glycine max - Graine Extraction ratio : 120:1 Dry plant equivalent : 1,800 mg Potency : 7.5 mg ÉAI Genistein | 66 mg | Not calculated |
| Glycine max Source : Glycine max - Graine Potency : 15 mg Soy isoflavones | Not specified | Not calculated |
| Ginkgo biloba Source : Feuille Extraction ratio : 50:1 Dry plant equivalent : 2,000 mg Potency : 24 % Flavonoid glycosides | 40 mg | Not calculated |
| Ginkgo biloba Source : Feuille Potency : 6 % Terpene lactones | Not specified | Not calculated |
| Humulus lupulus Source : Humulus lupulus - Strobile Extraction ratio : 20:1 Dry plant equivalent : 1,000 mg | 50 mg | Not calculated |
| 5-Hydroxy-L-tryptophane Source : Griffonia simplicifolia, graine | 50 mg | Not calculated |
| Glycine max Source : Glycine max - Graine Extraction ratio : 120:1 Dry plant equivalent : 1,800 mg Potency : 15 mg Soy isoflavones | 66 mg | Not calculated |
| Rhodiola rosea Source : Racine et rhizome Extraction ratio : 5:1 Dry plant equivalent : 750 mg Potency : 3 % Rosavin | 150 mg | Not calculated |
| Ginkgo biloba Source : Feuille Extraction ratio : 50:1 Dry plant equivalent : 2,000 mg Potency : 6 % Terpene lactones | 40 mg | Not calculated |
| Ginkgo biloba Source : Feuille Potency : 24 % Flavonoid glycosides | Not specified | Not calculated |
| Bêta-carotène Source : bêta-carotène | 9,000 mcg | Not calculated |
| Actaea racemosa Source : Racine et rhizome Extraction ratio : 6:1 Dry plant equivalent : 120 mg Potency : 2.5 % Triterpene glycosides | 20 mg | Not calculated |
Non-medicinal ingredients
Hypromellose, Cellulose microcristalline, Eau purifiée, Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Femmes ménopausées et en postménopause | Not specified | 1 Portion(s) | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
May reduce severe and frequent menopausal symptoms (such as hot flashes and/or night sweats etc.). Hops is traditionally used in Herbal Medicine to help relieve nervousness (sedative and/or calmative) or as a sleep aid (hypnotic).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80048891
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.